Neil Chester
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Neil Chester has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
David R. Mottram
School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool
1 shared publicationMark Powell
Quay Pharmaceuticals Limited, Bromborough, Wirral
1 shared publicationThomas Reilly
Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool
1 shared publication
Latest Publications
- 16 December 2003
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (1) , 62-67
Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control
Aims To study the elimination of ephedrines with reference to the International Olympic Committee (IOC) doping control cut‐off levels, following multiple dosing of over‐the‐counter decongestant preparations.Methods A double‐blind study was performed in which 16 healthy male volunteers were administered either pseudoephedrine or phenylpropanolamine in maximal recommended therapeutic doses over a 36‐h period. Urine was collected every two hours between 08:00 and 24:00 h and at 04:00 h throughout the testing period of three days. Urine drug levels were quantified using high performance liquid chromatography. Side‐effects were assessed, including heart rate and blood pressure, every four hours between 08:00 and 20:00 h.Results Mean (95% CI) total phenylpropanolamine and pseudoephedrine eliminated unchanged was 75 (88, 61) and 81 (92, 71)%, respectively. Maximum urine concentrations of phenylpropanolamine and pseudoephedrine were 112.1 (164.2, 59.9) and 148.5 (215.0, 82.1) mg.l−1, respectively. A peak in drug urine concentration occurred four hours following the final dose. There were no adverse cardiovascular effects and only mild CNS stimulation was evident.Conclusions Following therapeutic, multiple dosing, drug levels remain above the IOC cut‐off levels for a minimum of 6 h and 16 h following final doses of phenylpropanolamine and pseudoephedrine, respectively. Athletes require informed advice on this from their healthcare professionals.
- 16 December 2003
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 57 (1) , 62-67
Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control
Aims To study the elimination of ephedrines with reference to the International Olympic Committee (IOC) doping control cut‐off levels, following multiple dosing of over‐the‐counter decongestant preparations.Methods A double‐blind study was performed in which 16 healthy male volunteers were administered either pseudoephedrine or phenylpropanolamine in maximal recommended therapeutic doses over a 36‐h period. Urine was collected every two hours between 08:00 and 24:00 h and at 04:00 h throughout the testing period of three days. Urine drug levels were quantified using high performance liquid chromatography. Side‐effects were assessed, including heart rate and blood pressure, every four hours between 08:00 and 20:00 h.Results Mean (95% CI) total phenylpropanolamine and pseudoephedrine eliminated unchanged was 75 (88, 61) and 81 (92, 71)%, respectively. Maximum urine concentrations of phenylpropanolamine and pseudoephedrine were 112.1 (164.2, 59.9) and 148.5 (215.0, 82.1) mg.l−1, respectively. A peak in drug urine concentration occurred four hours following the final dose. There were no adverse cardiovascular effects and only mild CNS stimulation was evident.Conclusions Following therapeutic, multiple dosing, drug levels remain above the IOC cut‐off levels for a minimum of 6 h and 16 h following final doses of phenylpropanolamine and pseudoephedrine, respectively. Athletes require informed advice on this from their healthcare professionals.